Figure 6. Non-invasive bioluminescence monitoring of Zr-75-1 tumor xenograft bearing mice during the treatment phase.

(A) Tumor xenografts were established in nude mice using engineered Zr-75-1-CMV-Fluc2.Tdt reporter cells. Mice in ¹³¹I group received single intraperitoneal injection of 1mCi of ¹³¹I on day 0, and mice in VPA group received 5 doses of 250 mg/kg VPA treatment alone while the experimental group undergone pre-treatment with 250 mg/kg VPA for 5 days before ¹³¹I treatment started. (B) Graph illustrates mean bioluminescence signal quantities from sets of mice (n = 3) at day 0, day 5 and day 8 when the mice were scanned by injecting D-luciferin.